Back to search
Inherited Retinal Dystrophy Associated With RPE65 Mutations
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Inherited Retinal Dystrophy Associated With RPE65 Mutations trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Inherited Retinal Dystrophy Associated With RPE65 Mutations trials you may qualify forThe purpose of the study is to evaluate the safety, tolerability and efficacy of LX101 in subjects with biallelic RPE65 mutation-associated inherited retinal dy…
The purpose of the study is to evaluate the efficacy and safety of LX101 in subjects with biallelic RPE65 mutation-associated inherited retinal dystrophy. This…
The objective of this study is to collect long-term safety information (i.e., for 5 years after treatment) associated with voretigene neparvovec-rzyl (vector an…
Up to nine subjects who have participated in the earlier LX101 clinical study, and who meet all study eligibility criteria, will receive LX101 administration in…
The study is a Phase 3, open-label, randomized controlled trial of gene therapy intervention by subretinal administration of AAV2-hRPE65v2 (voretigene neparvove…
Multi-site, non-randomized, observational study, for up to 15 years after subretinal AAV2-hRPE65v2 administration for each subject. The study is a non-intervent…